arrow
M

Mathieu Ferrari

autolus
H指数:14
被引数:1,456

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis

CAR T细胞疗法选择性清除异种移植和人类类器官模型中骨髓纤维化的疾病驱动突变钙网蛋白细胞

2026-01-010
OA
Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia

抗CD21嵌合抗原受体T细胞治疗T细胞急性淋巴细胞白血病的临床前开发

2025-04-160
PRE
In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms
2024-12-100
PRE
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
2024-11-110
OAAI
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

双T细胞常数 β 链 (TRBC)1和TRBC2染色通过流式细胞术鉴定T细胞肿瘤

2024-02-295
OAAI
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies

T细胞恶性肿瘤中靶向TRBC1和TRBC2的免疫疗法的结构指导工程

2024-02-215
OAAI
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
2024-02-010
OAAI
Dual targeting of CD19 and CD22 against B-ALL a novel-sensitivity aCD22 CAR
2023-07-0117
OAAI
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

儿童和年轻成人复发或难治性b细胞急性淋巴细胞白血病患者中CD19和CD22双重靶向的CAR T细胞: 1期试验

2021-10-12163
OAAI
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
2021-09-0931
OAAI